BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 32731576)

  • 1. Antinociceptive and Cytotoxic Activity of Opioid Peptides with Hydrazone and Hydrazide Moieties at the C-Terminus.
    Dyniewicz J; Lipiński PFJ; Kosson P; Bochyńska-Czyż M; Matalińska J; Misicka A
    Molecules; 2020 Jul; 25(15):. PubMed ID: 32731576
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antinociceptive profile of potent opioid peptide AM94, a fluorinated analogue of biphalin with non-hydrazine linker.
    Mollica A; Costante R; Stefanucci A; Pinnen F; Lucente G; Fidanza S; Pieretti S
    J Pept Sci; 2013 Apr; 19(4):233-9. PubMed ID: 23136069
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antinociceptive Efficacy of the µ-Opioid/Nociceptin Peptide-Based Hybrid KGNOP1 in Inflammatory Pain without Rewarding Effects in Mice: An Experimental Assessment and Molecular Docking.
    Dumitrascuta M; Bermudez M; Trovato O; De Neve J; Ballet S; Wolber G; Spetea M
    Molecules; 2021 May; 26(11):. PubMed ID: 34071603
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In Vivo, In Vitro and In Silico Studies of the Hybrid Compound AA3266, an Opioid Agonist/NK1R Antagonist with Selective Cytotoxicity.
    Matalińska J; Lipiński PFJ; Kosson P; Kosińska K; Misicka A
    Int J Mol Sci; 2020 Oct; 21(20):. PubMed ID: 33086743
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Further Optimization and Evaluation of Bioavailable, Mixed-Efficacy μ-Opioid Receptor (MOR) Agonists/δ-Opioid Receptor (DOR) Antagonists: Balancing MOR and DOR Affinities.
    Harland AA; Yeomans L; Griggs NW; Anand JP; Pogozheva ID; Jutkiewicz EM; Traynor JR; Mosberg HI
    J Med Chem; 2015 Nov; 58(22):8952-69. PubMed ID: 26524472
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Development of novel LP1-based analogues with enhanced delta opioid receptor profile.
    Pasquinucci L; Turnaturi R; Prezzavento O; Arena E; Aricò G; Georgoussi Z; Parenti R; Cantarella G; Parenti C
    Bioorg Med Chem; 2017 Sep; 25(17):4745-4752. PubMed ID: 28734666
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Investigation of the interaction between the atypical agonist c[YpwFG] and MOR.
    Gentilucci L; Squassabia F; De Marco R; Artali R; Cardillo G; Tolomelli A; Spampinato S; Bedini A
    FEBS J; 2008 May; 275(9):2315-37. PubMed ID: 18397320
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Design of Analgesic Trivalent Peptides with Low Withdrawal Symptoms: Probing the Antinociceptive Profile of Novel Linear and Cyclic Peptides as Opioid Pan Ligands.
    Stefanucci A; Minosi P; Pieretti S; Tanguturi P; Molnar G; Scioli G; Marinaccio L; Della Valle A; Streicher JM; Mollica A
    ACS Chem Neurosci; 2023 Feb; 14(3):506-515. PubMed ID: 36651179
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bifunctional μ/δ opioid peptides: variation of the type and length of the linker connecting the two components.
    Ding J; Lemieux C; Chung NN; Schiller PW
    Chem Biol Drug Des; 2012 Feb; 79(2):186-93. PubMed ID: 22070627
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Redoubling the ring size of an endomorphin-2 analog transforms a centrally acting mu-opioid receptor agonist into a pure peripheral analgesic.
    Piekielna J; De Marco R; Gentilucci L; Cerlesi MC; Calo' G; Tömböly C; Artali R; Janecka A
    Biopolymers; 2016 May; 106(3):309-17. PubMed ID: 27038094
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Opioid peptidomimetics: leads for the design of bioavailable mixed efficacy μ opioid receptor (MOR) agonist/δ opioid receptor (DOR) antagonist ligands.
    Mosberg HI; Yeomans L; Harland AA; Bender AM; Sobczyk-Kojiro K; Anand JP; Clark MJ; Jutkiewicz EM; Traynor JR
    J Med Chem; 2013 Mar; 56(5):2139-49. PubMed ID: 23419026
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cyclic biphalin analogues with a novel linker lead to potent agonist activities at mu, delta, and kappa opioid receptors.
    Remesic M; Macedonio G; Mollica A; Porreca F; Hruby V; Lee YS
    Bioorg Med Chem; 2018 Jul; 26(12):3664-3667. PubMed ID: 29858157
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Discovery of Novel Multifunctional Ligands with μ/δ Opioid Agonist/Neurokinin-1 (NK1) Antagonist Activities for the Treatment of Pain.
    Giri AK; Apostol CR; Wang Y; Forte BL; Largent-Milnes TM; Davis P; Rankin D; Molnar G; Olson KM; Porreca F; Vanderah TW; Hruby VJ
    J Med Chem; 2015 Nov; 58(21):8573-83. PubMed ID: 26465170
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synthesis and Pharmacological Evaluation of Novel C-8 Substituted Tetrahydroquinolines as Balanced-Affinity Mu/Delta Opioid Ligands for the Treatment of Pain.
    Nastase AF; Griggs NW; Anand JP; Fernandez TJ; Harland AA; Trask TJ; Jutkiewicz EM; Traynor JR; Mosberg HI
    ACS Chem Neurosci; 2018 Jul; 9(7):1840-1848. PubMed ID: 29677442
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification and Pharmacological Characterization of a Low-Liability Antinociceptive Bifunctional MOR/DOR Cyclic Peptide.
    Li Y; Eans SO; Ganno-Sherwood M; Eliasof A; Houghten RA; McLaughlin JP
    Molecules; 2023 Nov; 28(22):. PubMed ID: 38005269
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Highly potent side chain-main chain cyclized dermorphin-deltorphin analogues: an integrated approach including synthesis, bioassays, NMR spectroscopy and molecular modelling.
    Ro S; Zhu Q; Lee CW; Goodman M; Darlak K; Spatola AF; Chung NN; Schiller PW; Malmberg AB; Yaksh TL
    J Pept Sci; 1995; 1(3):157-74. PubMed ID: 9222993
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Modulation of opioid receptor ligand affinity and efficacy using active and inactive state receptor models.
    Anand JP; Purington LC; Pogozheva ID; Traynor JR; Mosberg HI
    Chem Biol Drug Des; 2012 Nov; 80(5):763-70. PubMed ID: 22882801
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Synthesis and Structure-Activity Relationships of 5'-Aryl-14-alkoxypyridomorphinans: Identification of a μ Opioid Receptor Agonist/δ Opioid Receptor Antagonist Ligand with Systemic Antinociceptive Activity and Diminished Opioid Side Effects.
    Vekariya RH; Lei W; Ray A; Saini SK; Zhang S; Molnar G; Barlow D; Karlage KL; Bilsky EJ; Houseknecht KL; Largent-Milnes TM; Streicher JM; Ananthan S
    J Med Chem; 2020 Jul; 63(14):7663-7694. PubMed ID: 32530286
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Receptor binding properties and antinociceptive effects of chimeric peptides consisting of a micro-opioid receptor agonist and an ORL1 receptor antagonist.
    Kawano S; Ito R; Nishiyama M; Kubo M; Matsushima T; Minamisawa M; Ambo A; Sasaki Y
    Biol Pharm Bull; 2007 Jul; 30(7):1260-4. PubMed ID: 17603164
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Enkephalin analogues with N-phenyl-N-(piperidin-2-ylmethyl)propionamide derivatives: Synthesis and biological evaluations.
    Deekonda S; Cole J; Sunna S; Rankin D; Largent-Milnes TM; Davis P; BassiriRad NM; Lai J; Vanderah TW; Porecca F; Hruby VJ
    Bioorg Med Chem Lett; 2016 Jan; 26(1):222-7. PubMed ID: 26611918
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.